Author:
Peest D.,Ganser A.,Einsele H.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. o A (2009) Sekundäre Immundefektkrankheiten. In: Bundesärztekammer (Hrsg) Querschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten. Deutscher Ärzte-Verlag, Köln
2. o A (2013) Myeloma. In: Howlader N, Noone AM, Krapcho M et al (Hrsg) SEER Cancer Statistics Review, 1975–2010, based on November 2012 SEER data submission, National Cancer Institute. Bethesda. http://seer.cancer.gov/csr/1975_2010/
3. Armeson KE, Hill EG, Costa LJ (2013) Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 48:562–567
4. Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91–97
5. Barlogie B, Anaissie E, Rhee F van et al (2010) Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol 28:3023–3027
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Neue Arzneimittel 2013;Arzneiverordnungs- Report 2014;2014